DZ2751A1 - Composés calciolytiques nouveaux procédé pour leurpréparation et compositions pharmaceutiques les c ontenant. - Google Patents

Composés calciolytiques nouveaux procédé pour leurpréparation et compositions pharmaceutiques les c ontenant.

Info

Publication number
DZ2751A1
DZ2751A1 DZ990052A DZ990052A DZ2751A1 DZ 2751 A1 DZ2751 A1 DZ 2751A1 DZ 990052 A DZ990052 A DZ 990052A DZ 990052 A DZ990052 A DZ 990052A DZ 2751 A1 DZ2751 A1 DZ 2751A1
Authority
DZ
Algeria
Prior art keywords
calciolytic
preparation
new
pharmaceutical compositions
compositions containing
Prior art date
Application number
DZ990052A
Other languages
English (en)
French (fr)
Inventor
Pradip Kumar Bhatnagar
Joelle Lorraine Burgess
James Francis Callahan
Raul Rollando Calvo
Del Eric G Mar
Maria Amparo Lago
Thomas The Nguyen
Original Assignee
Smithkline Beecham Corp
Nps Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Corp, Nps Pharma Inc filed Critical Smithkline Beecham Corp
Application granted granted Critical
Publication of DZ2751A1 publication Critical patent/DZ2751A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/44—Iso-indoles; Hydrogenated iso-indoles
    • C07D209/48—Iso-indoles; Hydrogenated iso-indoles with oxygen atoms in positions 1 and 3, e.g. phthalimide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C255/00—Carboxylic acid nitriles
    • C07C255/01—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms
    • C07C255/32—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms having cyano groups bound to acyclic carbon atoms of a carbon skeleton containing at least one six-membered aromatic ring
    • C07C255/33—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms having cyano groups bound to acyclic carbon atoms of a carbon skeleton containing at least one six-membered aromatic ring with cyano groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by saturated carbon chains
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
    • C07C217/02—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C217/04—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C217/06—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one etherified hydroxy group and one amino group bound to the carbon skeleton, which is not further substituted
    • C07C217/14—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one etherified hydroxy group and one amino group bound to the carbon skeleton, which is not further substituted the oxygen atom of the etherified hydroxy group being further bound to a carbon atom of a six-membered aromatic ring
    • C07C217/18—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one etherified hydroxy group and one amino group bound to the carbon skeleton, which is not further substituted the oxygen atom of the etherified hydroxy group being further bound to a carbon atom of a six-membered aromatic ring the six-membered aromatic ring or condensed ring system containing that ring being further substituted
    • C07C217/22—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one etherified hydroxy group and one amino group bound to the carbon skeleton, which is not further substituted the oxygen atom of the etherified hydroxy group being further bound to a carbon atom of a six-membered aromatic ring the six-membered aromatic ring or condensed ring system containing that ring being further substituted by carbon atoms having at least two bonds to oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
    • C07C217/54—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
    • C07C217/56—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains not further substituted by singly-bound oxygen atoms
    • C07C217/60—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains not further substituted by singly-bound oxygen atoms linked by carbon chains having two carbon atoms between the amino groups and the six-membered aromatic ring or the condensed ring system containing that ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C255/00—Carboxylic acid nitriles
    • C07C255/01—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms
    • C07C255/32—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms having cyano groups bound to acyclic carbon atoms of a carbon skeleton containing at least one six-membered aromatic ring
    • C07C255/37—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms having cyano groups bound to acyclic carbon atoms of a carbon skeleton containing at least one six-membered aromatic ring the carbon skeleton being further substituted by etherified hydroxy groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C255/00—Carboxylic acid nitriles
    • C07C255/49—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C255/54—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing cyano groups and etherified hydroxy groups bound to the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C255/00—Carboxylic acid nitriles
    • C07C255/49—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C255/57—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing cyano groups and carboxyl groups, other than cyano groups, bound to the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/01—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms
    • C07C311/02—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • C07C311/03—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton having the nitrogen atoms of the sulfonamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C311/06—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton having the nitrogen atoms of the sulfonamide groups bound to hydrogen atoms or to acyclic carbon atoms to acyclic carbon atoms of hydrocarbon radicals substituted by carboxyl groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Rheumatology (AREA)
  • Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
DZ990052A 1998-04-08 1999-04-07 Composés calciolytiques nouveaux procédé pour leurpréparation et compositions pharmaceutiques les c ontenant. DZ2751A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US8109398P 1998-04-08 1998-04-08

Publications (1)

Publication Number Publication Date
DZ2751A1 true DZ2751A1 (fr) 2003-09-15

Family

ID=22162059

Family Applications (1)

Application Number Title Priority Date Filing Date
DZ990052A DZ2751A1 (fr) 1998-04-08 1999-04-07 Composés calciolytiques nouveaux procédé pour leurpréparation et compositions pharmaceutiques les c ontenant.

Country Status (34)

Country Link
US (1) US6395919B1 (bg)
EP (1) EP1070048B1 (bg)
JP (1) JP2002510671A (bg)
KR (1) KR20010042526A (bg)
CN (1) CN1304401A (bg)
AP (1) AP1271A (bg)
AR (1) AR018177A1 (bg)
AT (1) ATE303358T1 (bg)
AU (1) AU752389B2 (bg)
BG (1) BG104916A (bg)
BR (1) BR9909486A (bg)
CA (1) CA2327279A1 (bg)
CO (1) CO5031246A1 (bg)
DE (1) DE69927008T2 (bg)
DZ (1) DZ2751A1 (bg)
EA (1) EA200001039A1 (bg)
EG (1) EG24178A (bg)
ES (1) ES2247795T3 (bg)
HK (1) HK1034243A1 (bg)
HU (1) HUP0101346A3 (bg)
ID (1) ID27004A (bg)
IL (1) IL138918A0 (bg)
MX (1) MXPA00009844A (bg)
MY (1) MY121054A (bg)
NO (1) NO20005006D0 (bg)
NZ (1) NZ507288A (bg)
OA (1) OA11499A (bg)
PE (1) PE20000415A1 (bg)
PL (1) PL343357A1 (bg)
SK (1) SK14852000A3 (bg)
TR (1) TR200002896T2 (bg)
UA (1) UA58586C2 (bg)
WO (1) WO1999051569A1 (bg)
ZA (1) ZA200005369B (bg)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ECSP003590A (es) * 1999-07-31 2002-02-25 Smithkline Beecham Corp Compuestos calcioliticos
MY159417A (en) * 2000-01-24 2017-01-13 Smithkline Beecham Corp Calcilytic compounds
US20030018203A1 (en) 2002-07-17 2003-01-23 Largo Maria Amparo Calcilytic compounds
FR2812875B1 (fr) 2000-08-08 2003-12-12 Centre Nat Rech Scient Nouvelles diamines possedant une activite modulatrice des casr et leur mode de preparation
ATE411275T1 (de) * 2000-08-11 2008-10-15 Japan Tobacco Inc Calciumrezeptor-antagonisten
ES2273909T3 (es) * 2000-10-25 2007-05-16 Smithkline Beecham Corporation Compuestos calciliticos.
MY143244A (en) 2002-11-26 2011-04-15 Smithkline Beecham Corp Calcilytic compounds
WO2004069793A2 (en) 2003-01-28 2004-08-19 Bristol-Myers Squibb Company Novel 2-substituted cyclic amines as calcium sensing receptor modulators
US7205322B2 (en) 2003-02-12 2007-04-17 Bristol-Myers Squibb Company Thiazolidine compounds as calcium sensing receptor modulators
EP2308828A3 (en) * 2003-04-23 2013-05-22 Japan Tobacco Inc. CaSR antagonist
EP1630157A4 (en) 2003-05-28 2007-05-23 Japan Tobacco Inc ANTAGONIST OF CASR
US7265145B2 (en) 2003-05-28 2007-09-04 Bristol-Myers Squibb Company Substituted piperidines and pyrrolidines as calcium sensing receptor modulators and method
JP2007522148A (ja) * 2004-02-06 2007-08-09 スミスクライン・ビーチャム・コーポレイション カルシウム受容体アンタゴニスト化合物
US7648965B2 (en) * 2004-05-14 2010-01-19 Unigene Laboratories Inc. Method for fostering bone formation and preservation
US7531518B2 (en) * 2004-05-14 2009-05-12 Unigene Laboratories Inc. Method for fostering bone formation and preservation
US20060293667A1 (en) * 2005-05-19 2006-12-28 Agnes Vignery Bone implant device and methods of using same
EP1937233B1 (en) * 2005-09-02 2013-01-09 Amgen Inc. Modulating intestinal fluid balance using calcimimetics
ES2449340T3 (es) * 2007-03-30 2014-03-19 Amgen Inc. Compuestos calcimiméticos para su uso en el tratamiento de trastornos intestinales
NZ593676A (en) * 2008-12-24 2012-06-29 Daiichi Sankyo Co Ltd Calcium-sensing receptor antagonists
WO2010103429A1 (en) 2009-03-10 2010-09-16 Pfizer Inc. 1,1-(Dimethyl-Ethylamino)-2-Hydroxy-Propoxy]-Ethyl}-3-Methyl-Biphenyl-4- Carboxylic Acid Derivatives As Calcium Receptor Antagonists
GB201217330D0 (en) 2012-09-28 2012-11-14 Univ Cardiff Therapeutic for treating inflammatory lung disorders

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2533210A1 (fr) * 1982-09-17 1984-03-23 Lyon I Universite Claude Edulcorants de synthese
DE3301198A1 (de) * 1983-01-15 1984-07-19 Hoechst Ag, 6230 Frankfurt N-arylalkylamin-3-propoxypyridin-derivate, verfahren zu ihrer herstellung, sie enthaltende pharmazeutische praeparate und deren verwendung
US5541204A (en) * 1994-12-02 1996-07-30 Bristol-Myers Squibb Company Aryloxypropanolamine β 3 adrenergic agonists
WO1997010822A1 (en) * 1995-09-21 1997-03-27 Eli Lilly And Company SELECTIVE β3 ADRENERGIC AGONISTS
IL126458A (en) * 1996-04-09 2004-06-20 Nps Pharma Inc Calcium receptor inhibiting calcilytic compounds

Also Published As

Publication number Publication date
HUP0101346A3 (en) 2003-03-28
DE69927008T2 (de) 2006-03-16
AU752389B2 (en) 2002-09-19
DE69927008D1 (de) 2005-10-06
EA200001039A1 (ru) 2001-04-23
PE20000415A1 (es) 2000-05-21
NO20005006L (no) 2000-10-04
BR9909486A (pt) 2001-11-06
KR20010042526A (ko) 2001-05-25
US6395919B1 (en) 2002-05-28
UA58586C2 (uk) 2003-08-15
AP1271A (en) 2004-04-21
IL138918A0 (en) 2001-11-25
PL343357A1 (en) 2001-08-13
AR018177A1 (es) 2001-10-31
CA2327279A1 (en) 1999-10-14
CO5031246A1 (es) 2001-04-27
HK1034243A1 (en) 2001-10-19
ATE303358T1 (de) 2005-09-15
SK14852000A3 (sk) 2001-05-10
OA11499A (en) 2004-05-05
AU3481999A (en) 1999-10-25
CN1304401A (zh) 2001-07-18
ES2247795T3 (es) 2006-03-01
NO20005006D0 (no) 2000-10-04
EP1070048A1 (en) 2001-01-24
EP1070048B1 (en) 2005-08-31
ID27004A (id) 2001-02-22
AP2000001931A0 (en) 2000-09-30
TR200002896T2 (tr) 2001-01-22
BG104916A (bg) 2001-06-29
MXPA00009844A (es) 2003-07-14
EP1070048A4 (en) 2001-11-07
MY121054A (en) 2005-12-30
NZ507288A (en) 2003-05-30
ZA200005369B (en) 2001-12-18
WO1999051569A1 (en) 1999-10-14
JP2002510671A (ja) 2002-04-09
EG24178A (en) 2008-09-28
HUP0101346A2 (hu) 2001-08-28

Similar Documents

Publication Publication Date Title
DZ2751A1 (fr) Composés calciolytiques nouveaux procédé pour leurpréparation et compositions pharmaceutiques les c ontenant.
DZ2457A1 (fr) Derivés de nicotinamide nouveaux procédé pour leurpréparation et compositions pharmaceutiques les c ontenant.
DZ2128A1 (fr) Composés nouveaux, procédé pour leur préparation et compositions pharmaceutiques les contenant.
DZ2891A1 (fr) Dérivés de tétrahydroquinoléines substués nouveaux, procédé pour leur préparation et compositions pharmaceutiques les contenant.
FR2718136B1 (fr) Composés aromatiques aminés, procédé pour leur obtention et compositions pharmaceutiques les contenant.
FR2780057B1 (fr) Phenoxypropanolamines, procede pour leur preparation et compositions pharmaceutiques les contenant
MA26687A1 (fr) 4-carboxyamino-2-methyl-1,2,3,4-tetrahydroquinoleines, procede pour leur preparation et compositions pharmaceutiques les contenant
DZ2745A1 (fr) BicycloÄ2.2.1Üheptanes nouveaux procédé pour leur préparation et compositions pharmaceutiques les contenant.
DZ2890A1 (fr) 4-Carboxamino-2-substitué-1,2,3,4-tétrahydroquinoléines, procédé pour leur préparation et compositions pharmaceutiques les contenant.
CY2537B1 (fr) Composés hétérocycliques substitués, procédé pour leur préparation et compositions pharmaceutiques les contenant
MA26659A1 (fr) Dérivés de benzimidazole nouveaux, compositions pharmaceutiques les contenant et procédé pour leur préparation.
DZ1889A1 (fr) Dérivés de quinoléine nouveaux, procédé pour leur préparation et compositions pharmaceutiques les contenant.
DZ2300A1 (fr) Dérivés 6,5-hétérobicycliques substitués, procédé pour leur préparation et compositions pharmaceutiques les contenant.
DZ2299A1 (fr) Dérivés 6,6-hétérobicycliques substitués, procédé pour leur préparation et compositions pharmaceutiques les contenant.
DZ2773A1 (fr) Pyrazolopyrimidinones nouvelles procédé pour leur préparation et compositions pharmaceutiques les contenant.
DZ2376A1 (fr) Dérivés de sulfonamides nouveaux procédé pour leurpréparation et compositions pharmaceutiques les c ontenant.
DZ2962A1 (fr) Dérivés de 3-azabicycloÄ3,1,0Ühexane nouveaux, procédé pour leur préparation et compositions les contenant.
DZ2634A1 (fr) Dérivés de pleuromutiline nouveaux procédé pour leur préparation et compositions pharmaceutiques lescontenant.
MA26686A1 (fr) Derives de 4,4-biarylpiperidine nouveaux, procede pour leur preparation et compositions pharmaceutiques les contenant
MA26630A1 (fr) 4-phenylpyperidines nouvelles, procede pour leur preparation et compositions pharmaceutiques les contenant
DZ1957A1 (fr) Dérivés de pipéridine nouveaux, procédé pour leur préparation et compositions pharmaceutiques les contenant.
DZ2395A1 (fr) Composés nouveaux a noyau dibenzocycloheptène procédé pour leur préparation et compositions pharmaceutiques les contenant.
DZ2777A1 (fr) Dérivés de quinazolinamines nouveaux procédé pour leur préparation et compositions pharmaceutiques les contenant.
DZ2866A1 (fr) 1-Aryl-3-arylméthyl-1,8-naphtyridine-4-(1H)-ones nouvelles, procédé pour leur préparation et compositions pharmaceutiques les contenant.
MA26558A1 (fr) Derives nouveaux de 6-0-methylerythromycine a, procede pour leur preparation et compositions pharmaceutiques les contenant.